Cambridge's science and engineering industry is pulling in new investment, with five local companies raising money. New funding rounds were recently announced by science and engineering firms GNS Healthcare, Spero Therapeutics and Leuko Labs, according to company database Crunchbase.
GNS Healthcare topped the city's recent funding headlines by announcing a $23 million Series D round on July 9, led by Cigna Ventures.
According to its Crunchbase profile, "GNS Healthcare is a healthcare analytics company. They focus on advancing and applying industrial-scale data analytics to empower key healthcare stakeholders to solve complex care, treatment and cost challenges."
The 20-year-old company has raised nine previous funding rounds, including a $6 million round in 2017.
Next up, Spero Therapeutics raised $5.9 million in grant funding, in a round announced on July 16 and financed by the U.S. Department of Defense.
According to Crunchbase, "Spero Therapeutics is developing first-in-class therapeutics for treatment of Gram-negative infections. The company leverages a top-tier chemistry and microbiology team, an efficient virtual approach to drug development and a focus on high potential, novel mechanisms to fill the unmet need for early-stage therapeutics targeting serious bacterial infections."
Founded in 2013, the company has raised seven previous rounds, including a $75 million round in 2018.
Meanwhile, Leuko Labs raised $1.8 million in seed funding, announced on July 18. The round's investors were led by Good Growth Capital.
From the company's Crunchbase profile, "Leuko Labs develops non-invasive white blood cell monitoring device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life-threatening infections worldwide."
Leuko Labs last raised seed funding earlier this year.
In total, Cambridge-based science and engineering companies have raised $38 million in venture funding over the past month and $4.3 billion over the past year.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
